|

Clinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence

RECRUITINGSponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University
Actively Recruiting
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Started2025-12-01
Est. completion2028-12-30
Eligibility
SexFEMALE
Healthy vol.Accepted

Summary

Breast cancer is one of the most common malignancies in women worldwide, and distant metastasis is the main cause of poor prognosis and death. This project aims to construct a precision prediction system based on multi-omics (digital pathology, immunohistochemistry, proteomics, gene sequencing) and artificial intelligence to predict distant and organ-specific metastasis (bone, lung, liver, brain) in breast cancer, analyze its mechanisms, and provide new solutions for precision medicine.

Eligibility

Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

1. Female patients pathologically diagnosed with breast cancer at our hospital or participating centers between January 1, 2000, and December 30, 2028.
2. Must meet one of the following: 1) Initially diagnosed with breast cancer at our hospital, has developed distant metastasis (liver, bone, lung, or brain), and has a biopsy or surgical specimen from the metastatic site stored at our hospital, with complete clinical information available. 2) Primary tumor specimen is not at our hospital, but a biopsy or surgical specimen from a distant metastatic site (liver, bone, lung, brain) is stored at our hospital.

Exclusion Criteria:

1. Concomitant metastatic malignancy from another primary cancer.
2. Incomplete clinical information.

Conditions4

BreastBreast CancerCancerPathology

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.